

Crohn's Disease Prognostic Serological Marker Profile

Introduction

Crohn's disease (CD) is a chronic inflammatory bowel disease causing considerable morbidity with a prevalence of 26 to 199 cases per 100,000 in North America.¹ The etiology of CD remains unclear, but it is thought to be caused by a combination of genetic, environmental, and immunoregulatory factors that lead to a wide variety of clinical presentations and manifestations.²

In order to help discern the individual patient's clinical course a classification system was created that subcategorizes disease behavior to noncomplicated disease (nonstricturing and nonpenetrating) or complicated disease (stricturing or penetrating) and also subcategorizes age at diagnosis and disease location.³ Due to the clinical variability of the disease there is no single test for the diagnosis, prognosis, and assessment of CD activity and severity. The physician, therefore, must rely on a combination of symptoms, clinical examination, laboratory indices, radiology, endoscopy with histology, and (most recently) serological marker assays in order to choose the best treatment management scheme for the individual patient.²⁻⁴

The management of CD includes a variety of pharmacological and surgical interventions and depends on disease location, severity, and complications.^{4,5} There are numerous pharmacological/biological treatments available for CD patients. For patients with mild disease, physicians typically prescribe treatments that may have less efficacy but are associated with fewer side effects. As patients develop or present with more moderate to severe disease, treatments such as corticosteroids, immunomodulators, or biological therapy may be prescribed. These treatments are more efficacious but are associated with more serious side effects.

Given the heterogeneous nature of CD, the choice of therapy should be tailored to the patient's clinical course, and predictors of prognosis are necessary.⁶ LabCorp's Crohn's disease prognostic profile using Glycominds IBDX serology panel employs serological markers that have been associated with more aggressive CD disease and may aid in the prediction of the clinical course of CD patients.⁷⁻¹¹

Marker Origin Related to Pathophysiology

Cellular and humoral immune responses rely heavily on interactions between glycans and specific glycan-binding proteins.¹² IBDX anti-


bodies most likely respond to cell surface glycan antigens. gASCA and AMCA antibodies are directed against mannan antigens, which are found in the cell wall of the yeast *S cerevisiae*.⁷⁻⁹ ALCA, ACCA and gASCA also appear to be directed against glycans found in the cell wall of the pathogenic fungus *Candida albicans*.¹³ Furthermore, these antibodies were found to associate with CD susceptible mutations in pattern recognition receptor genes.¹⁴ Most notable is that the antibodies included in the profile were reported as being elevated in serum of CD patients with more aggressive disease. Though the exact cause of elevated antibody levels has not been deciphered, this phenomenon may be the result of the enhanced permeability of the epithelial layer of the gastrointestinal tract.¹⁵

Stratifying CD Phenotypes

The Crohn's Disease Prognostic Profile is a serological marker profile based on the detection of circulating antibodies directed against glycans. The panel includes:

- ACCA – Antichitobioside Carbohydrate Antibodies
- ALCA – Antilaminaribioside Carbohydrate Antibodies
- AMCA – Antimannobioside Carbohydrate Antibodies
- gASCA – Anti-*Saccharomyces cerevisiae* Antibodies

The IBDX antibodies are detected in patient serum or plasma by an indirect solid-phase enzyme-linked immunosorbent assay (ELISA). ALCA, ACCA, and AMCA were found to be positive in approximately 44% of ASCA-negative CD patients.⁷ The Crohn's Disease Prognostic Profile panel of antibodies can be used by physicians to aid in stratifying patients already diagnosed with CD. The panel should not be used as a sole decision tool for deciding on a CD patient's treatment plan, but it should be used in conjunction with other clinical data and tests such as natural history of the patient's disease, family history, patient smoking status, and endoscopy results. CD patients are considered to be at greater risk for disease complication (stricturing or penetrating) or surgery intervention if they are positive for two or more serological markers. Patients who had antibody response to two or more markers had an increased risk of complicated disease (OR: 3.12, 95% CI 2.27 to 4.29, $p < 0.0001$), need for CD-related abdominal surgery (OR: 2.81, 95% CI 2.07 to 3.80, $p < 0.0001$) and ileal involvement (OR: 2.19, 95% CI 1.50 to 3.30, $p = 0.0001$) compared to patients with one or no positive antibody.⁸

In another cohort similar results were reported, whereas patients who had antibody response to two or more markers had an increased risk of complicated disease (OR: 2.92, 95% CI 1.92 to 4.46, $p < 0.0001$), need for CD-related abdominal surgery (OR: 2.55, 95% CI 1.68 to 3.87, $p < 0.0001$) and ileal involvement (OR: 2.16, 95% CI 1.35 to 3.43, $p = 0.007$) compared to patients with no positive antibodies.⁹ IBDX antibodies were also shown to be able to predict patients who are at a higher risk for first complication (HR: 1.9 to 2.4, $p < 0.007$).¹⁰ Ongoing clinical trials may provide additional information regarding this relationship. 

Crohn's Disease Prognostic Profile* 162020

Related Information Inflammatory Bowel Disease (IBD) Profile (164830)

Synonyms Glycominds; IBDX

Test Includes Antichitobioside carbohydrate antibodies (ACCA); antilaminaribioside carbohydrate antibodies (ALCA); antimannobioside carbohydrate antibodies (AMCA); anti-*Saccharomyces cerevisiae* antibodies (ASCA)

Specimen Serum

Volume 1 mL

Minimum Volume 0.2 mL

Container Red-top tube or gel-barrier tube

Storage Instructions Refrigerate

Causes for Rejection Hemolysis; lipemia; heat-treated specimen; gross bacterial contamination

Use Prognostic aid for use in the clinical management of patients who have been diagnosed with Crohn's disease.

Limitations The absence of antibody reactivity in this panel, although associated with increased incidence of a more benign course, does not preclude the future development of more complicated disease or need for surgery.⁸

Methodology Enzyme immunoassay (EIA)

*For the most current information regarding test options, including specimen requirements and CPT codes, please consult the online Test Menu at www.LabCorp.com.

References

- Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterol*. 2004 May; 126(6):1504-1517.
- Dotan I. Serologic markers in inflammatory bowel disease: Tools for better diagnosis and disease stratification. *Expert Rev Gastroenterol Hepatol*. 2007 Dec; 1(2), 265-274.
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*. 2005 Sep; 19(Suppl A):5-36.
- Hanauer SB, Sandborn W. Management of Crohn's disease in adults; Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol*. 2001 Mar; 96(3):635-643.
- Ruthuff B. Clinical review of Crohn's disease. *J Am Acad Nurse Pract*. 2007 Aug; 19(8):392-397.
- Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. *Gastroenterol*. 2007 Jul; 133(1):312-339.
- Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. *Gastroenterol*. 2006 Aug; 131(2):366-378.
- Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. *Gut*. 2007 Oct; 56(10):1394-1403.

- Papp M, Altortjay I, Dotan N, et al. Hungarian IBD Study Group, Lakatos PL. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. *Am J Gastroenterol*. 2008 Mar; 103(3):665-681.
- Rieder F, Wolf A, Schleder S, et al. The novel anti-glycan antibodies Anti-L and Anti-C in conjunction with ALCA, ACCA, gASCA and AMCA predict early development of fistulae, stenoses and surgery in patients with Crohn's disease: A prospective analysis. *Gastroenterol*. 2008; 134(Supl 1):A-53.
- Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. *World J Gastroenterol*. 2008 Sep 7; 14(33):5115-5124.
- Alavi A, Axford JS. The pivotal nature of sugars in normal physiology and disease. *Wien Med Wochenschr*. 2006 Jan; 156(1-2):19-33.
- Sendid B, Dotan N, Nseir S, et al. Antibodies against glucan, chitin, and *Saccharomyces cerevisiae* mannan as new biomarkers of *Candida albicans* infection that complement tests based on *C albicans* mannan. *Clin Vaccine Immunol*. 2008 Dec; 15(12):1868-1877.
- Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. *Gut*. 2007 Nov; 56(11):1536-1542.
- Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease—an alliance gone bad. *Am J Physiol Gastrointest Liver Physiol*. 2008 Dec; 295(6):G1139-G1149.



www.LabCorp.com